Prostate Cancer Imaging with Novel PET Tracers

Liza Lindenberg; Peter Choyke; William Dahut

doi:10.1007/s11934-016-0575-5

Prostate Cancer Imaging with Novel PET Tracers

Curr Urol Rep. 2016 Mar;17(3):18. doi: 10.1007/s11934-016-0575-5.

Authors

Liza Lindenberg^{1

2}, Peter Choyke^{3

4}, William Dahut^{5

6}

Affiliations

¹ Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. [email protected].
² Molecular Imaging Program, National Cancer Institute, BG 10 RM B3B69F MS 1002, 10 Center Dr, Bethesda, MD, 20814, USA. [email protected].
³ Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. [email protected].
⁴ Molecular Imaging Program, National Cancer Institute, BG 10 RM B3B69F MS 1002, 10 Center Dr, Bethesda, MD, 20814, USA. [email protected].
⁵ Center for Cancer Research, National Cancer Institute, BG 10-CRC RM 3-2571 MSC 1206, 10 Center Dr, Bethesda, MD, 20892-1206, USA. [email protected].
⁶ Genitourinary Malignancies Branch, National Cancer Institute, BG 10 RM B3B402 MS 1088, 10 CENTER DR, Bethesda, MD, 20814, USA. [email protected].

Abstract

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.

Keywords: 11C acetate; 11C/18F choline; 18F DCFBC; 18F DHT; 18F FACBC; 18F NaF; 68Ga PSMA.

Publication types

Review

MeSH terms

Antigens, Surface / metabolism
Glutamate Carboxypeptidase II / metabolism
Humans
Male
Multimodal Imaging
Positron-Emission Tomography*
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / enzymology
Radiopharmaceuticals
Tomography, X-Ray Computed

Substances

Antigens, Surface
Radiopharmaceuticals
FOLH1 protein, human
Glutamate Carboxypeptidase II

Grants and funding

ZIA BC010655-14/Intramural NIH HHS/United States